Statement: There was the same number of anemic patinets in both cohorts of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 116/396 (29.29%)   Anaemia 3/396 (0.76%)   Febrile neutropenia 20/396 (5.05%)   Granulocytopenia 1/396 (0.25%)   Leukopenia 1/396 (0.25%)   Neutropenia 19/396 (4.80%)   Atrial fibrillation 3/396 (0.76%)   Cardiac failure congestive 0/396 (0.00%)   Coronary artery disease 0/396 (0.00%)   Left ventricular dysfunction 7/396 (1.77%)   Myocardial infarction 3/396 (0.76%) Adverse Events 2:   Total: 160/408 (39.22%)   Anaemia 3/408 (0.74%)   Febrile neutropenia 46/408 (11.27%)   Granulocytopenia 0/408 (0.00%)   Leukopenia 0/408 (0.00%)   Neutropenia 18/408 (4.41%)   Atrial fibrillation 0/408 (0.00%)   Cardiac failure congestive 2/408 (0.49%)   Coronary artery disease 1/408 (0.25%)   Left ventricular dysfunction 6/408 (1.47%)   Myocardial infarction 0/408 (0.00%)